Trials / Recruiting
RecruitingNCT07229729
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
A Randomized, Open-label, Multicenter Phase II Clinical Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A2102 | SHR-A2102. |
| DRUG | Adebrelimab | Adebrelimab. |
| DRUG | Paclitaxel | Paclitaxel. |
| DRUG | Carboplatin | Carboplatin. |
| DRUG | Alomnertinib Mesilate | Alomnertinib Mesilate. |
| DRUG | Furmonertini Mesilate | Furmonertini Mesilate. |
| DRUG | Osimertinib Mesylate | Osimertinib Mesylate. |
Timeline
- Start date
- 2025-11-24
- Primary completion
- 2026-10-01
- Completion
- 2029-10-01
- First posted
- 2025-11-17
- Last updated
- 2025-12-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07229729. Inclusion in this directory is not an endorsement.